ClinicalTrials.gg
CompletedNCT02761629Updated Aug 16, 2016Results posted

Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus

A Phase 4 interventional study of Peg-Interferon Alpha-2A and Ribavirin in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 17 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-16.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 175 studies testing ribavirin in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. Ribavirin · Hepatitis C, Chronic.

Enrollment
64th of 174
180 · median 107
Started
2005
with 16 others
Phase 4
55 of 175
none open now
Registered
163rd of 175
by date
Lead sponsor
28 of 175
Hoffmann-La Roche

Among the 175 studies testing ribavirin in Hepatitis C, Chronic, this one is the 64th largest by enrollment of the 174 interventional ones that give a count, is one of 17 that started in 2005, is one of 55 in phase 4, and was the 163rd registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 175 studies testing ribavirin in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About ribavirin

Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 175 studies testing ribavirin in Hepatitis C, Chronic as a file.
02

Study summary

This randomized, multi-center, Phase IV, comparative study will assess the efficacy and safety of combined peg-interferon alpha-2a (Peg-IFN-Alpha-2A) and ribavirin therapy for 48 or 72 weeks of treatment and 24 weeks of follow-up in participants with Genotype 1 chronic hepatitis C (CHC), co-infected with human immunodeficiency virus type 1 (HIV-1).

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Serological evidence of chronic infection by anti-hepatitis C virus (HCV) test
  • Detectable HCV-ribonucleic acid (RNA) plasma level testing by Roche AMPLICOR HCV (\<50 International Units per milliliter [IU/mL]) (qualitative test)
  • Chronic liver disease consistent with infection of CHC
  • Compensated liver disease ( Grade A)
  • Serological evidence of infection by -1 test, anti-HIV-1 or HIV-1 RNA detection
  • Negative pregnancy urine or blood test (for women in childbearing age); additionally, all men and women of must agree to use two effective forms of during the treatment and during the 6 months after the end of treatment

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing women and male partners of pregnant women
  • Prior therapy with interferon (IFN) or ribavirin and any medication less than or equal to (\</=) 6 weeks before the first dose of the study drug
  • History or other evidence of a medical condition associated with chronic liver disease further than
  • Active opportunistic infection associated with and / or cancer requiring systemic therapy
  • History of any other significant illness which in the investigator's opinion, could result in the participant's inability to meet the Protocol requirements
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks

    Participants will receive Peg-IFN-Alpha-2A and ribavirin for 48 weeks.

    Drug: Peg-Interferon Alpha-2A · Drug: Ribavirin

  • Active comparator
    Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks

    Participants will receive Peg-IFN-Alpha-2A and ribavirin for 72 weeks.

    Drug: Peg-Interferon Alpha-2A · Drug: Ribavirin

Interventions

  • DrugPeg-Interferon Alpha-2A

    Peg-IFN-Alpha-2A will be administered at 180 micrograms (mcg) once weekly via subcutaneous injection.

    Also known as: Pegasys, Peg-IFN-Alpha-2A

  • Ribavirin will be administered as either 1000 milligrams (mg) (2\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing less than (\<) 75 kilograms (kg) or as 1200 mg (3\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing greater than or equal to (\>/=) 75 kg.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response (SVR)

    SVR was defined as having un-detectable hepatitis C virus (HCV) ribonucleic acid (RNA) levels 24 weeks after completion of study treatment. HCV RNA levels were measured using Roche COBAS AMPLICOR HCV Test (limit of detection: 50 International Units per milliliter \[IU/mL\]). Participants with detectable HCV RNA or without measurement at the end of the 24 week after completion of study treatment were considered as non-responders.

    Time frame: 24 weeks after completion of study treatment (up to Week 72 for "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm and up to Week 96 for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm)

Secondary outcomes

  1. Percentage of Participants With Undetectable HCV RNA

    HCV RNA levels were measured using Roche COBAS AMPLICOR HCV Test (limit of detection: 50 IU/mL). Data for this outcome measure was to be reported up to end of treatment visit (Week 48 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).

    Time frame: For "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm: Weeks 4, 12, 24, and 48; for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm: Weeks 4, 12, 24, 48, and 72

  2. Percentage of Participants With Undetectable HCV RNA 12 Weeks After the Last Dose of Peg-IFN-Alpha-2A

    HCV RNA levels were measured using Roche COBAS AMPLICOR HCV Test (limit of detection: 50 IU/mL). Participants with detectable HCV RNA or without measurement at the end of 12 weeks after the last dose of Peg-IFN-Alpha-2A were considered as non-responders.

    Time frame: 12 weeks after the last dose of Peg-IFN-Alpha-2A (up to Week 60 for "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm and up to Week 84 for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm)

  3. Percentage of Participants Without SVR Among Participants With Undetectable HCV RNA at the End of Treatment

    SVR was defined as having undetectable HCV RNA levels 24 weeks after completion of study treatment. HCV RNA levels were measured using Roche COBAS AMPLICOR HCV Test (limit of detection: 50 IU/mL). Percentage of participants without SVR among participants with undetectable HCV RNA at the end of treatment was reported (end of treatment = Week 48 for "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm and Week 72 for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm).

    Time frame: 24 weeks after completion of study treatment (up to Week 72 for "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm and up to Week 96 for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm)

  4. Serum Human Immunodeficiency Virus (HIV) RNA Levels

    HIV RNA levels were measured using Roche AMPLICOR MONITOR HIV-1 Test (limit of detection: 400 HIV-1 RNA copies/mL). Data for this outcome measure was to be reported up to 24 weeks after end of treatment visit (Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 96 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).

    Time frame: For "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm: Weeks 4, 12, 24, 48, and 72; for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm: Weeks 4, 12, 24, 48, 72, and 96

  5. Change From Baseline in Cluster of Differentiation (CD) 4 (CD4) Cell Counts at Weeks 4, 12, 24, 48, 72, and 96

    Data for this outcome measure was to be reported up to 24 weeks after end of treatment visit (Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 96 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).

    Time frame: For "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm: Baseline, Weeks 4, 12, 24, 48, and 72; for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm: Baseline, Weeks 4, 12, 24, 48, 72, and 96

  6. Change From Baseline in CD4/CD8 Ratio at Weeks 4, 12, 24, 48, 72, and 96

    Data for this outcome measure was to be reported up to 24 weeks after end of treatment visit (Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 96 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).

    Time frame: For "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm: Baseline, Weeks 4, 12, 24, 48, and 72; for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm: Baseline, Weeks 4, 12, 24, 48, 72, and 96

  7. Percentage of Participants With Alanine Aminotransferase (ALT) Level Categories

    ALT levels were classified as: Normal Limit (NL) (as per laboratory standard), \>1-2 Upper Normal Limit (ULN), \>2-5 ULN, \>5-10 ULN, and \>10 ULN. Percentage of participants in each of these ALT level categories was reported. Data for this outcome measure was to be reported up to 24 weeks after end of treatment visit (Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 96 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).

    Time frame: For "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm: Weeks 4, 12, 24, 48, and 72; for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm: Weeks 4, 12, 24, 48, 72, and 96

07

Results

Posted Aug 16, 2016

Participant flow

Participant flow — Overall Study
MilestonePeg-IFN-Alpha-2A+Ribavirin - 48 WeeksPeg-IFN-Alpha-2A+Ribavirin - 72 Weeks
Started9090
Treated8286
Completed6358
Not completed2732
Withdrew: Adverse event/intercurrent illness75
Withdrew: Insufficient therapeutic response27
Withdrew: Failure to return24
Withdrew: Did not cooperate/refused treatment24
Withdrew: Protocol violation22
Withdrew: Withdrawal by subject03
Withdrew: Other02
Withdrew: Lost to follow-up41
Withdrew: Randomized but not treated84

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response (SVR)

SVR was defined as having un-detectable hepatitis C virus (HCV) ribonucleic acid (RNA) levels 24 weeks after completion of study treatment. HCV RNA levels were measured using Roche COBAS AMPLICOR HCV Test (limit of detection: 50 International Units per milliliter \[IU/mL\]). Participants with detectable HCV RNA or without measurement at the end of the 24 week after completion of study treatment were considered as non-responders.

Time frame:
24 weeks after completion of study treatment (up to Week 72 for "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm and up to Week 96 for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm)
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response (SVR)
percentage of participantsPeg-IFN-Alpha-2A+Ribavirin - 48 WeeksPeg-IFN-Alpha-2A+Ribavirin - 72 Weeks
Percentage of Participants With Sustained Virologic Response (SVR)23.8 (15.0 to 34.6)36.5 (26.3 to 47.6)
Statistical analysis
  • Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks vs Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks · Fisher Exact · p = 0.0536 · Difference in response rates: 12.7 · 95% CI -0.01 to 26.6Exact 95% confidence interval was from the binomial distribution for response rate.
SecondaryPercentage of Participants With Undetectable HCV RNA

HCV RNA levels were measured using Roche COBAS AMPLICOR HCV Test (limit of detection: 50 IU/mL). Data for this outcome measure was to be reported up to end of treatment visit (Week 48 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).

Time frame:
For "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm: Weeks 4, 12, 24, and 48; for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm: Weeks 4, 12, 24, 48, and 72
Reported as:
Number · percentage of participants
Percentage of Participants With Undetectable HCV RNA
percentage of participantsPeg-IFN-Alpha-2A+Ribavirin - 48 WeeksPeg-IFN-Alpha-2A+Ribavirin - 72 Weeks
Week 4 (n=73, 83)2.7 (0.3 to 9.6)12.0 (5.9 to 21.0)
Week 12 (n=73, 81)23.3 (14.2 to 34.7)28.4 (18.9 to 39.5)
Week 24 (n=73, 78)52.1 (40.0 to 63.9)53.8 (42.2 to 65.2)
Week 48 (n=68, 71)55.9 (43.3 to 67.9)64.8 (52.5 to 75.8)
Week 72 (n=0, 65)NA (NA to NA)56.9 (44.0 to 69.2)
SecondaryPercentage of Participants With Undetectable HCV RNA 12 Weeks After the Last Dose of Peg-IFN-Alpha-2A

HCV RNA levels were measured using Roche COBAS AMPLICOR HCV Test (limit of detection: 50 IU/mL). Participants with detectable HCV RNA or without measurement at the end of 12 weeks after the last dose of Peg-IFN-Alpha-2A were considered as non-responders.

Time frame:
12 weeks after the last dose of Peg-IFN-Alpha-2A (up to Week 60 for "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm and up to Week 84 for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm)
Reported as:
Number · percentage of participants
Percentage of Participants With Undetectable HCV RNA 12 Weeks After the Last Dose of Peg-IFN-Alpha-2A
percentage of participantsPeg-IFN-Alpha-2A+Ribavirin - 48 WeeksPeg-IFN-Alpha-2A+Ribavirin - 72 Weeks
Percentage of Participants With Undetectable HCV RNA 12 Weeks After the Last Dose of Peg-IFN-Alpha-2A23.8 (15.0 to 34.6)36.5 (26.3 to 47.6)
SecondaryPercentage of Participants Without SVR Among Participants With Undetectable HCV RNA at the End of Treatment

SVR was defined as having undetectable HCV RNA levels 24 weeks after completion of study treatment. HCV RNA levels were measured using Roche COBAS AMPLICOR HCV Test (limit of detection: 50 IU/mL). Percentage of participants without SVR among participants with undetectable HCV RNA at the end of treatment was reported (end of treatment = Week 48 for "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm and Week 72 for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm).

Time frame:
24 weeks after completion of study treatment (up to Week 72 for "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm and up to Week 96 for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm)
Reported as:
Number · percentage of participants
Percentage of Participants Without SVR Among Participants With Undetectable HCV RNA at the End of Treatment
percentage of participantsPeg-IFN-Alpha-2A+Ribavirin - 48 WeeksPeg-IFN-Alpha-2A+Ribavirin - 72 Weeks
Percentage of Participants Without SVR Among Participants With Undetectable HCV RNA at the End of Treatment52.624.3
Statistical analysis
  • Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks vs Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks · Fisher Exact · p = 0.0175
SecondarySerum Human Immunodeficiency Virus (HIV) RNA Levels

HIV RNA levels were measured using Roche AMPLICOR MONITOR HIV-1 Test (limit of detection: 400 HIV-1 RNA copies/mL). Data for this outcome measure was to be reported up to 24 weeks after end of treatment visit (Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 96 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).

Time frame:
For "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm: Weeks 4, 12, 24, 48, and 72; for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm: Weeks 4, 12, 24, 48, 72, and 96
Reported as:
Mean · Log10 copies per milliliter
Serum Human Immunodeficiency Virus (HIV) RNA Levels
Log10 copies per milliliterPeg-IFN-Alpha-2A+Ribavirin - 48 WeeksPeg-IFN-Alpha-2A+Ribavirin - 72 Weeks
Baseline (n=12, 23)4.23 ± 0.824.64 ± 0.74
Week 4 (n=6, 16)3.94 ± 0.383.98 ± 0.69
Week 24 (n=9, 20)3.96 ± 0.364.21 ± 0.72
Week 48 (n=11, 17)4.02 ± 0.654.41 ± 0.75
Week 72 (n=10, 9)4.08 ± 0.784.51 ± 0.85
Week 96 (n=0, 13)NA ± NA4.22 ± 0.85
SecondaryChange From Baseline in Cluster of Differentiation (CD) 4 (CD4) Cell Counts at Weeks 4, 12, 24, 48, 72, and 96

Data for this outcome measure was to be reported up to 24 weeks after end of treatment visit (Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 96 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).

Time frame:
For "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm: Baseline, Weeks 4, 12, 24, 48, and 72; for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm: Baseline, Weeks 4, 12, 24, 48, 72, and 96
Reported as:
Mean · Cells per cubic millimeter (cells/mm^3)
Change From Baseline in Cluster of Differentiation (CD) 4 (CD4) Cell Counts at Weeks 4, 12, 24, 48, 72, and 96
Cells per cubic millimeter (cells/mm^3)Peg-IFN-Alpha-2A+Ribavirin - 48 WeeksPeg-IFN-Alpha-2A+Ribavirin - 72 Weeks
Baseline (n=78, 81)578.7 ± 277.1546.2 ± 278.8
Change at Week 4 (n=69, 74)-148.2 ± 197.5-88.0 ± 154.9
Change at Week 12 (n=68, 75)-185.4 ± 192.7-164.5 ± 193.9
Change at Week 24 (n=69, 68)-206.7 ± 217.0-178.4 ± 207.5
Change at Week 48 (n=61, 67)-209.4 ± 242.4-196.4 ± 226.4
Change at Week 72 (n=58, 55)9.5 ± 188.9-167.5 ± 235.8
Change at Week 96 (n=0, 62)NA ± NA-15.1 ± 212.2
SecondaryChange From Baseline in CD4/CD8 Ratio at Weeks 4, 12, 24, 48, 72, and 96

Data for this outcome measure was to be reported up to 24 weeks after end of treatment visit (Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 96 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).

Time frame:
For "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm: Baseline, Weeks 4, 12, 24, 48, and 72; for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm: Baseline, Weeks 4, 12, 24, 48, 72, and 96
Reported as:
Mean · Ratio
Change From Baseline in CD4/CD8 Ratio at Weeks 4, 12, 24, 48, 72, and 96
RatioPeg-IFN-Alpha-2A+Ribavirin - 48 WeeksPeg-IFN-Alpha-2A+Ribavirin - 72 Weeks
Baseline (n=78, 81)0.67 ± 0.390.68 ± 0.44
Change at Week 4 (n=69, 74)0.11 ± 0.420.09 ± 0.21
Change at Week 12 (n=68, 75)0.22 ± 0.310.20 ± 0.27
Change at Week 24 (n=69, 68)0.36 ± 0.510.29 ± 0.30
Change at Week 48 (n=61, 67)0.43 ± 0.470.30 ± 0.43
Change at Week 72 (n=58, 55)0.12 ± 0.410.36 ± 0.43
Change at Week 96 (n=0, 62)NA ± NA0.09 ± 0.35
SecondaryPercentage of Participants With Alanine Aminotransferase (ALT) Level Categories

ALT levels were classified as: Normal Limit (NL) (as per laboratory standard), \>1-2 Upper Normal Limit (ULN), \>2-5 ULN, \>5-10 ULN, and \>10 ULN. Percentage of participants in each of these ALT level categories was reported. Data for this outcome measure was to be reported up to 24 weeks after end of treatment visit (Week 72 for 'Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks' arm and Week 96 for 'Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks' arm).

Time frame:
For "Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks" arm: Weeks 4, 12, 24, 48, and 72; for "Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks" arm: Weeks 4, 12, 24, 48, 72, and 96
Reported as:
Number · percentage of participants
Percentage of Participants With Alanine Aminotransferase (ALT) Level Categories
percentage of participantsPeg-IFN-Alpha-2A+Ribavirin - 48 WeeksPeg-IFN-Alpha-2A+Ribavirin - 72 Weeks
Week 4, NL (n=70, 78)50.052.6
Week 4, >1-2 ULN (n=70, 78)40.038.5
Week 4, >2-5 ULN (n=70, 78)10.09.0
Week 4, >5-10 ULN (n=70, 78)0.00.0
Week 4, >10 ULN (n=70, 78)0.00.0
Week 12, NL (n=76, 77)61.862.3
Week 12, >1-2 ULN (n=76, 77)27.629.9
Week 12, >2-5 ULN (n=76, 77)10.55.2
Week 12, >5-10 ULN (n=76, 77)0.01.3
Week 12, >10 ULN (n=76, 77)0.01.3
Week 24, NL (n=74, 74)70.363.5
Week 24, >1-2 ULN (n=74, 74)27.028.4
Week 24, >2-5 ULN (n=74, 74)2.76.8
Week 24, >5-10 ULN (n=74, 74)0.00.0
Week 24, >10 ULN (n=74, 74)0.01.4
Week 48, NL (n=65, 71)67.769.0
Week 48, >1-2 ULN (n=65, 71)24.626.8
Week 48, >2-5 ULN (n=65, 71)7.72.8
Week 48, >5-10 ULN (n=65, 71)0.01.4
Week 48, >10 ULN (n=65, 71)0.00.0
Week 72, NL (n=59, 61)52.568.9
Week 72, >1-2 ULN (n=59, 61)27.127.9
Week 72, >2-5 ULN (n=59, 61)20.33.3
Week 72, >5-10 ULN (n=59, 61)0.00.0
Week 72, >10 ULN (n=59, 61)0.00.0
Week 96, NL (n=0, 62)NA50.0
Week 96, >1-2 ULN (n=0, 62)NA35.5
Week 96, >2-5 ULN (n=0, 62)NA12.9
Week 96, >5-10 ULN (n=0, 62)NA1.6
Week 96, >10 ULN (n=0, 62)NA0.0

Adverse events

Collected over 96 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks—7/82 (8.5%)79/82 (96.3%)
Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks—12/86 (14%)81/86 (94.2%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPeg-IFN-Alpha-2A+Ribavirin - 48 WeeksPeg-IFN-Alpha-2A+Ribavirin - 72 Weeks
Pneumonia NOSInfections and infestations1/820/86
Postoperative infectionInfections and infestations1/820/86
Respiratory tract infection NOSInfections and infestations1/821/86
Diarrhoea NOSGastrointestinal disorders1/820/86
Mouth ulcerationGastrointestinal disorders1/820/86
HypothyroidismEndocrine disorders1/820/86
Influenza like illnessGeneral disorders1/820/86
Lip and/or oral cavity cancer NOSNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/820/86
Pregnancy NOSPregnancy, puerperium and perinatal conditions1/820/86
DepressionPsychiatric disorders1/820/86
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPeg-IFN-Alpha-2A+Ribavirin - 48 WeeksPeg-IFN-Alpha-2A+Ribavirin - 72 Weeks
HeadacheNervous system disorders34/8241/86
MyalgiaMusculoskeletal and connective tissue disorders38/8233/86
Anaemia NOSBlood and lymphatic system disorders31/8225/86
PyrexiaGeneral disorders30/8232/86
AstheniaGeneral disorders23/8230/86
FatigueGeneral disorders26/8227/86
AnorexiaMetabolism and nutrition disorders25/8222/86
InsomniaPsychiatric disorders14/8223/86
NauseaGastrointestinal disorders21/8220/86
Vomiting NOSGastrointestinal disorders9/8217/86

Baseline characteristics

Intent-to-treat (ITT) analysis population included all randomized participants who receive at least one dose of any study medication and have at least one post-baseline efficacy assessment.

Age, Continuous
Age, Continuous(years)Peg-IFN-Alpha-2A+Ribavirin - 48 WeeksPeg-IFN-Alpha-2A+Ribavirin - 72 WeeksTotal
Mean42.3 ± 7.942.2 ± 8.442.3 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Peg-IFN-Alpha-2A+Ribavirin - 48 WeeksPeg-IFN-Alpha-2A+Ribavirin - 72 WeeksTotal
Female312657
Male4959108
08

Study locations

17 sites
  • Campinas, 13081-970, Brazil
  • Florianopolis, 88032-001, Brazil
  • Itajaí, 88302-202, Brazil
  • Juiz de Fora, 36036-330, Brazil
  • Porto Alegre, 90020-160, Brazil
  • Recife, 52050-150, Brazil
  • Ribeirão Preto, 14048-900, Brazil
  • Rio de Janeiro, 20270-901, Brazil
  • Rio de Janeiro, 21045-900, Brazil
  • Rio de Janeiro, 21941-590, Brazil
  • Rio Grande, 96200-310, Brazil
  • Santo Andre, 09060-650, Brazil
  • Santos, 11045-904, Brazil
  • Sao Paulo, 01246-000, Brazil
  • Sao Paulo, 04039-004, Brazil
  • Sao Paulo, 04040-002, Brazil
  • Sao Paulo, 05403, Brazil
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 8 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2016
First posted
May 4, 2016
Start
Apr 2005
Primary completionActual
May 2008
CompletionActual
May 2008
Results first posted
Aug 16, 2016
Last update
Aug 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02761629
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 4, 2016
Start date
Apr 2005
Primary completion
May 2008
Completion
May 2008
Results posted
Aug 16, 2016
Last update
Aug 16, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribavirin

Start the discussion